EHA 2023 again featured a plethora of interesting oral abstracts and poster presentations in the field of acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). In this article, we will highlight some of the most promising data with regard to AML clinical studies, novel combinations in the treatment of AML and risk stratification. Furthermore, we will discuss some important clinical updates in the field of MDS.

(BELG J HEMATOL 2023;14(5):221–5)